What is Converge?
Converge operates at the vanguard of the biotechnology sector, utilizing advanced Generative AI to transform how drug discovery is conducted. By training Large Language Models on the unique syntax of biological systems, the company enables pharmaceutical researchers to predict complex molecular interactions and disease mechanisms with unprecedented accuracy. This computational approach transcends traditional methods, allowing for the rapid identification of novel molecular candidates and the contextualization of biological data. As a key player in the AI-driven drug development market, Converge provides the essential tools required to navigate the complexities of signaling pathways, ultimately reducing the time and cost associated with bringing life-saving therapies to market.
How much funding has Converge raised?
Converge has raised a total of $33M across 3 funding rounds:
Angel/Seed
$5.5M
Series A
$25M
Grant
$2.5M
Angel/Seed (2024): $5.5M with participation from TLV Partners
Series A (2026): $25M led by Vintage Investment Partners, Bessemer Venture Partners, TLV Partners, and Saras Capital
Grant (2026): $2.5M supported by Bill & Melinda Gates Foundation
Key Investors in Converge
TLV Partners
An Israeli venture capital firm specializing in early-stage startups, focusing on category-defining companies in AI, healthcare, and application security.
Vintage Investment Partners
A firm with over $3.6 billion in assets that acts as a strategic partner by delivering invaluable insights and connecting portfolio companies with a vast network of investors.
Bessemer Venture Partners
A long-standing venture capital firm with a global presence, known for its extensive history of supporting transformative technology and healthcare enterprises.
What's next for Converge?
With the recent influx of capital, Converge is poised to scale its operations and deepen its research capabilities. The strategic focus will likely shift toward enhancing the predictive power of its LLMs and expanding its footprint within the global pharmaceutical ecosystem. By leveraging its recent funding, the company aims to forge deeper partnerships with biotech firms, providing them with the predictive insights necessary to streamline their R&D workflows. As the industry continues to embrace AI-native solutions, Converge is well-positioned to lead the transition toward a more data-driven, efficient, and precise model of drug discovery, setting a new standard for innovation in the life sciences sector.
See full Converge company page
